Immune modulation and sepsis

International Journal of Clinical Practice

Volumn 51, Issue 4, 1997, Pages 232-237

  Karzai, W ^a   Reinhart, K ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; STEROID; THROMBOCYTE ACTIVATING FACTOR; TOXIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INFLAMMATION; MEDIATOR; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SURVIVAL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; CYTOKINES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; PLATELET ACTIVATING FACTOR; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030804091     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
2. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAAM 1995; 273: 934-941.
3. Fisher CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-1702.
4. Schreuder WO, Schneider AJ, Groenveld ABJ et al. Effects of dopamine vs norepinephrine on hemodynamics in septic shock. Chest 1989; 95: 1282-1288.
5. Bone RC. Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis. Crit Care Med 1992; 20: 884-890.
6. Bone RC. Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis. Crit Care Med 1992: 20: 891-898.
7. Bone RC. Modulators of coagulation: a critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-1389.
8. Cobb JP, Cunnion RE, Danner RL. Nitric oxide as a target for therapy in septic shock. Crit Care Med 1993; 21: 1261-1263.
9. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996; 77: 110-117.
10. Schröder J, Stuber F, Gallati H et al. Pattern of soluble TNF receptors I and II in sepsis. Infection 1995; 23: 143-148.
11. Zeni F, Vindimian M, Pain P et al. Anti-inflammatory and proinflammatory cytokines in patients with severe sepsis (letter). J Infect Dis 1995; 172: 1171-1172.
12. Goldie AS, Fearon KC, Ross JA et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995; 274: 172-177.
13. Moldawer LL. Interleukin-1, TNF alpha and their naturally occurring antagonists in sepsis. Blood Purif 1993; 11: 128-133.
14. Dhainaut JF, Tenaillon A, Le Tulzo Y et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22: 1720-1728.
15. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med 1993; 21: S415-S422.
16. Michie HR, Manogue KR, Spriggs DRet al. Detection of tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486.
17. Eichenholz PW, Eichacker PQ, Hoffman WD et al.. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 1992; 263: H668-H675.
18. Tracey KJ, Fong Y, Hesse DG et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
19. Beutler B, Millsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 229: 869-871.
20. Gardlund B, Sjolin J, Nilsson A et al. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995; 172: 296-301.
21. Herrmann JL, Blanchard H, Brunengo P et al. TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein kinetic values. Infection 1994; 22: 309-315.
22. Fisher CJ Jr, Opal SM, Dhainaut JF et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318-327.
23. Cohen J, Carlet J, The INTERSEPT Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis. Crit Care Med 1996; 24: 1431-1440.
24. Reinhart K, Wiegend-Löhnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742.
25. Leighton A, Pittet D. Suter PM et al. Ro-45-2081 (TNFR55-IgG1): Phase II placebo controlled study of 3 different single doses of Ro-45-2081 in severe sepsis/septic shock: prevalence of organ dysfunction. Intens Care Med 1994; 22: S432 (Abstract)
26. Fekade D, Knox K, Hussein K et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335: 311-315.
27. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
28. Cannon JG, Tompkins RG, Gelfand JA et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 160: 79-84.
29. Girardin E, Grau GE, Dayer J-M et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397-400
30. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-778.
31. Calandra T, Baumgartner JD, Grau GE et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and imerferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161: 982-989.
32. Ohlsson K, Björk P, Bergenfeldt M et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-552.
33. Fischer E, Marano MA, Van Zee KJ et al. Interleukin-1 receptor antagonist blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host response to sublethal endotoxaemia. J Clin Invest 1992; 89: 1551-1557.
34. Fisher CJ Jr, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994; 22: 12-21.
35. Fisher CJ, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-1843.
36. Koltai M, Hosford D, Braquet PG Platelet-Activating Factor in septic shock. New Horizons 1993; 1: 87-95.
37. Hinshaw LB, Archer LT, Beller BK et al. Survival in primates in lethal septic shock following delayed treatment with steroid. Circ Shock 1981; 8: 291-300.
38. Pitcairn M, Schuler J, Erne P et al. Glucocorticoids and antibiotic effects on experimental gram-negative bacteremic shock. Arch Surg 1975; 110: 1012-1017.
39. Cronin L, Cook DJ, Carlet J et al. Corticoid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-1439.
40. Bone RC, Fisher CJ, Clemmer TP et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
41. The Veterans Administration Systemic Sepsis Cooporative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659-665.
42. Hoffman SL, Punjabi NH, Kumar A et al. Reduction in mortality in chloramphenicol treated severe typhoid fever by high dose dexamethasone. N Engl J Med 1984; 310: 82-88.
43. Lebel MH, Freij BJ, Syrogainopolous GA et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind placebo-controlled trials. N Engl J Med 1988; 319: 964-971.
44. Dale DC, Liles WC, Summer WR et al. Review: granulocyte colony-stimulating factor - role and relationships in infectious diseases. J Infect Dis 1995; 172: 1061-1075.
45. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325: 164-170.
46. Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. Clin Infect Dis 1994; 18 (Suppl): S197-S204.
47. Eichacker PQ, Natanson C. Rethinking the anti-inflammatory approach to septic shock. In: Vincent JL, Ed. Yearbook of Intensive Care and Emergency Medicine 1996. Heidelberg: Springer Verlag, 1996; 165-176.
48. Karzai W, Natanson C, Patterson M et al. The pulmonary effects of granulocyte colony stimulating factor (G-CSF) during pneumonia and oxygen exposure in nonneutropenic rats. Am J Resp Crit Care Med 1994; 149: A241 (Abstract).
49. Nelson S, Farkas S, Fotheringham N et al. Filgastrim in the treatment of hospitalized patients with community acquired pneumonia (CAP). Am J Resp Crit Care Med 1996; A535 (Abstract)
50. Lukacs NW, Strieter RM, Chensue SW et al. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 1995; 154: 5411-5417.
51. Moore FD, Socher SH, Davis C. Tumor necrosis factor and endotoxin can cause neutrophil activation through separate pathways. Arch Surg 1991; 126: 70-73.
52. Alexander HR, Sheppard BC, Jenson JC et al. Treatment with recombinant human tumor necrosis factor-alpha protects rats against lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest 1991; 88: 34-39.
53. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-2569.
54. Eschtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381: 75-77.
55. Schein M, Wittmann DH, Holzheimer R et al. Compartmentalization of cytokines in intra-abdominal infection. Surgery 1996; 119: 694-700.
56. Chorinchath BB, Kong LY, Mao L et al. Age-associated differences in TNF-alpha and nitric oxide production in endotoxic mice. J Immunol 1996; 156: 1525-1530.
57. Stuber F, Petersen M, Bokelmann F et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-384.
58. Assicot M, Gendrel D, Carsin H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
59. Eichacker PQ, Waisman Y, Natanson C et al. Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 1994; 77: 2366-2373.
60. Bagby GJ, Plessala KJ, Wilson LA et al. Divergent efficacy of antibody to tumor necrosis factor alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163: 83-88.
61. Nelson S, Summer WR, Nakamura C et al, Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanoltreated rats. J Infect Dis 1991; 164: 901-906.
62. Dhainaut JF, Vincent JL, Richard C et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-1469.